In a world of shifting trade dynamics and evolving regulatory frameworks, the life sciences sector must continuously adapt to stay competitive. As global supply chains evolve and regulatory landscapes grow more complex, Contract Research Organisations (CROs) play an increasingly vital role—offering the agility, scientific depth, and operational flexibility required to manage uncertainty and accelerate innovation.

Within this context, India is emerging as a strategic destination for drug discovery and development. Its strong foundation in chemistry and biology, combined with cost efficiency, regulatory maturity, and rapid innovation cycles, makes it a compelling partner for global biopharma companies. The recently finalised India–UK Free Trade Agreement further strengthens this position, with an expected boost of £25.5 billion in bilateral trade by 2040—lowering tariffs and creating new opportunities for collaboration in the life sciences. (Source: Reuters)

As this landscape evolves, India’s role as a hub for discovery services is becoming increasingly central — and the momentum is just getting started.

Kind regards,
Sunil Shah,
Co-founder, o2h Discovery

Why partner with o2h Discovery?

With over 25 years of scientific excellence, o2h Discovery is a trusted partner in accelerating drug discovery for biotech and pharma innovators worldwide. Our integrated multi-modality platform operating from Cambridge, UK, and Ahmedabad, India, strategically leverages India’s expanding scientific ecosystem to reduce risk, compress timelines, and enhance research outcomes across every stage of drug discovery.

We have the in-house capabilities to execute hit-to-lead optimisation programmes leading into patent and IND filing, all from our state-of-the-art biotechnology incubator. Our team offers deep expertise in discovery chemistry, biology, pharmacology, and the ongoing project management of preclinical development.

o2h Discovery is also expanding into emerging modalities. Our multidisciplinary teams are advancing novel programs in RNA therapeutics, immuno-oncology, targeted protein degradation (TPD/PROTACs), integrin biology, mitochondrial research, and psychedelic-inspired therapeutics. These efforts are supported by an expanded fragment library, a PROTAC toolbox, LNP formulation expertise, and novel peptide synthesis with non-GMP scale-up facilities.

To know more about our capabilities, please visit: https://o2hdiscovery.co 

Let’s discuss your discovery pipeline

At o2h Discovery, we love seeding new ideas in life sciences, aiming to foster a collaborative environment that drives scientific breakthroughs. Whether you're scaling up, pivoting, or simply looking for a reliable CRO partnership, we are ready to help you accelerate your drug discovery journey. 

Let’s connect and explore how we can support your next breakthrough.